Bayer anticipates its profits and sales to remain largely unchanged by 2026, as the company navigates ongoing uncertainties related to pesticide litigation. Bloomberg posted on X, highlighting Bayer's forecast amidst its legal challenges. The German pharmaceutical and life sciences company is facing significant hurdles in managing lawsuits concerning its pesticide products. Despite these challenges, Bayer remains committed to stabilizing its financial outlook over the next few years. The company is actively working to address the litigation issues while maintaining its market position and operational efficiency. Bayer's efforts to contain the legal disputes are crucial to its future financial performance, as the company aims to mitigate risks and ensure steady growth.